NexEos Bio's lead therapeutic NTX-1024 is a sterile eye drop containing a proprietary compound and formulation for the chronic treatment of vernal keratoconjunctivitis (VKC), with potential for future expansion into atopic keratoconjunctivitis (AKC) and perennial allergic conjunctivitis (PAC). These conditions are forms of chronic allergic conjunctivitis, often marked by persistent eosinophil-mediated inflammation.
NexEos has achieved positive results from an open-label, investigator-initiated study evaluating the efficacy, safety, and tolerability of NTX-1024 eye drops in adults with vernal keratoconjunctivitis (VKC). The study enrolled 15 patients with mild to moderate VKC who received NTX-1024 four times daily over a four-week period.
Treatment led to significant improvement in patient-reported symptoms such as itching and quality of life, along with reductions in clinical signs of inflammation, including hyperemia and corneal fluorescein staining. NTX-1024 was also found to be safe and well-tolerated.
VKC is a rare and severe eosinophil-driven ocular condition that can lead to irreversible ocular damage, including vision loss, if left untreated.
“VKC is a debilitating condition that severely impacts patients’ daily lives. The improvements observed with NTX-1024 offer promising new hope in improving symptoms and restoring ocular health in these patients.”
Dr. Ken Mandell, Program Lead, Vision Health
NTX-1024 offers patients a non-systemic and well-tolerated option to treat eosinophilic conjunctivitis, improving quality of life by treating symptoms such as itching, burning, tearing, and clinical signs of epithelial damage.
Current treatments for chronic allergy-based conjunctivitis include oral and topical antihistamines and corticosteroids. Due to common use of topical and oral corticosteroids, glaucoma is a potential complication of treatment.
NTX-1024 targets inflammatory proteins in the ocular tear film that are associated with allergic diseases. Our proprietary glycosaminoglycan resides on the ocular tear film only, where it targets inflammatory proteins to relieve symptoms.